Ardelyx, Inc. (ARDX)
Automate Your Wheel Strategy on ARDX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARDX
- Rev/Share 1.5158
- Book/Share 0.6105
- PB 5.8314
- Debt/Equity 1.0647
- CurrentRatio 4.123
- ROIC -0.1203
- MktCap 851747800.0
- FreeCF/Share -0.2042
- PFCF -17.4789
- PE -15.8012
- Debt/Assets 0.3781
- DivYield 0
- ROE -0.3445
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ARDX | H.C. Wainwright | -- | Buy | -- | $10 | June 18, 2025 |
| Downgrade | ARDX | Raymond James | Strong Buy | Outperform | -- | $11 | May 2, 2025 |
| Resumed | ARDX | Ladenburg Thalmann | -- | Buy | -- | -- | March 7, 2025 |
| Initiation | ARDX | BTIG Research | -- | Buy | -- | $14 | March 4, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
An Investigation Has Commenced on Behalf of Ardelyx, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARDX Losses
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - ARDX
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX)
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ARDX
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress
Read More
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Negative
Ardelyx's Q1 earnings reveal a sequential drop in revenue and a sharp rise in SG&A expenses, leading to a substantial operational loss. The company faces reimbursement challenges for XPHOZAH, raising concerns about its future profitability and market position. Despite having solid liquidity, Ardelyx's high cash burn rate and debt pose sustainability risks, making its current valuation seem inflated.
Read More
Tenapanor Approved in China for Hyperphosphatemia
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
Read More
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Negative
Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments.
Read More
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Read More
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz – Citigroup Dennis Ding – Jefferies Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison – BTIG Ryan Deschner - Raymond James Thomas Yip - H.C.
Read More
Ardelyx (ARDX) Meets Q4 Earnings Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Ardelyx (ARDX) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Read More
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales
Read More
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
Read More
About Ardelyx, Inc. (ARDX)
- IPO Date 2014-06-19
- Website https://www.ardelyx.com
- Industry Biotechnology
- CEO Mr. Michael G. Raab
- Employees 395